glp-1 obesity drugs news today Study predicts 16 new may come to market Dozens of new obesity drugs

Tirzepatide displayed an unprecedented glucose and body weight lowering potential, presenting also with the ability to increase insulin sensitivity, reduce systolic blood pressure and inflammation and ameliorate dyslipidemia, particularly by reducing triglycerides levels

The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.

ConclusionGLP-1 medications can be a helpful tool for weight loss, but theyre not a one-size-fits-all solution

For external use only

Learn If GLP-1 Is the Same as Ozempic and How It Can Support Your Weight Loss Journey in Las Vegas, NV and Beverly Hills, CA.

THURSDAY, Dec